ASP7517
BiologicalIntravenous (IV)
NCT Number: NCT04079296
The purpose of this study was to evaluate the safety and tolerability and to determine the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of ASP7517.
This study also evaluated the clinical response of ASP7517 as well as other measures of anticancer activity of ASP7517.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Site JP81005, Nagoya, Aichi-ken, Japan
This study consisted of 2 parts: phase 1 dose escalation and phase 2 dose expansion.
Phase 1 Dose Escalation:
Approximately 18 subjects with either relapsed/refractory (R/R) AML or R/R higher risk MDS were enrolled. Participants received 2 single doses of ASP7517 via intravenous infusion. Dosing occured on day 1 of each cycle. Each cycle was defined as 28 days with a total of 2 treatment cycles.
Participants were managed under hospitalization for at least 7 days during the first cycle of the dose escalation phase. In addition, prior to hospital discharge, participant safety was ensured by performing medical tests and procedures listed on day 7 of cycle 1 and tests considered clinically necessary to evaluate the participant's general condition and adverse event (AE) resolution. The participant was also followed on an outpatient basis on planned visits during cycles 1 and 2 after hospital discharge during the dose limiting toxicity (DLT) assessment period to closely monitor any AEs. Participants were hospitalized days 1 to 7 during cycle 2.
Phase 2 Dose Expansion:
Approximately 104 participants per dose level were enrolled. Each dose level enrolled up to 52 R/R AML participants and up to 52 R/R higher risk MDS participants. Both groups of participants were enrolled in parallel and independently. The number of dose levels investigated during phase 2 were based upon the data from phase 1. When escalation and expansion cohorts were both open for enrollment, enrollment into escalation cohorts took priority such that participants who were eligible for both were preferentially enrolled in the escalation cohorts.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous (IV)
Time frame: Day 1 up to 28 days
DLT was defined as any of the following events that occurred within 28 days starting with the first dose on cycle 1 day 1 (C1D1) and that was considered to be related to study drug. DLT was defined as follows:
Time frame: From first dose up to 43 months
An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE could therefore be any unfavorable & unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An AE was considered "serious" if, it resulted in any of the following outcomes: results in death; is life-threatening; results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions; results in congenital anomaly, or birth defect; requires inpatient hospitalization; or leads to prolongation of hospitalization; other medically important events. TEAE was defined as an AE observed after starting administration of the study drug. TEAEs included both Serious and non-serious AEs.
Time frame: From first dose up to 43 months
Percentage of participants with CRc was reported. CRc:defined as rate of all complete & incomplete remissions (CR + CR with incomplete platelet recovery [CRp] + CR with incomplete hematological recover [Cri]). CR: achieved morphologic leukemia-free state & their bone marrow was regenerating normal hematopoietic cells. If absolute neutrophil count (ANC) ≥ 1×10^9/L, platelet count (PC) ≥ 100×10^9/L, normal marrow differential < 5% blasts, & were red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion & platelet transfusion prior to disease assessment). There was no evidence of extramedullary leukemia or Auer rods & blast counts in peripheral blood must be ≤ 2%. CRp: must achieve CR except for incomplete platelet recovery (< 100×10^9/L). CRi: must fulfil CR except for incomplete hematological recovery with residual neutropenia (ANC < 1×10^9/L), with or without complete platelet recovery. RBC and platelet transfusion independence not required.
Time frame: From first dose up to 43 months
Percentage of participants with CR+BM CR+ PR was reported. CR, BM CR and PR achieved for minimum of 4 weeks; CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood)
BM CR: bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment
PR: achieved all CR criteria except bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5%, cellularity and morphology not relevant.
Time frame: C1D2
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C1D4
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C1D8
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C1D11
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C1D15
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C1D18
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C1D22
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C1D25
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C2D1
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C2D2
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C2D4
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C2D8
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C2D15
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C2D22
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C3D1
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C3D15
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C4D1
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C4D15
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C5D1
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C5D15
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C6D1
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: C6D15
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
Time frame: EOT (up to 63 Days)
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
EOT was calculated as last dose plus 7 days.
Time frame: EOT (up to 175 days)
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
EOT was calculated as last dose plus 7 days.
Time frame: OP (week 2)
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose.
Time frame: OP (week 4)
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose.
Time frame: OP (week 6)
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose.
Time frame: OP (week 8)
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose.
Time frame: OP (week 10)
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose.
Time frame: OP (week 12)
Number of participants with ECOG PS was reported. ECOG performance status was measured on a 6 point grade scale.
0: Fully active, able to carry on all pre-disease performance without restriction.
OP was the period observed after the last dose.
Time frame: From first response up to 43 months
DR for AML: included duration of CRc, duration of CR/complete remission with partial hematologic recovery (CRh), duration of CRh, duration of CR, and duration of response (i.e., CRc + PR).
CRh: achieved marrow blasts < 5%, partial hematologic recovery ANC ≥ 0.5 × 10^9/L and platelets ≥ 50 × 10^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%.
PR for AML; achieved bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts with decrease of at least 50% in the percentage of blasts in bone marrow aspirate with total marrow blasts between 5% and 25%. Value ≤ 5% blasts was considered PR if Auer rods were present. No evidence of extramedullary leukemia.
CR, CRc were defined in outcome measure #3. Kaplan Meier (KM) Estimate was used.
Time frame: From first response up to 43 months
DR for MDS: included duration of CR and duration of response (i.e., CR + BM CR + PR).
CR, BM CR and PR achieved for minimum of 4 weeks; CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood)
BM CR: bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pretreatment
PR: achieved all CR criteria except bone marrow blasts decreased by ≥ 50% over pretreatment but still > 5%, cellularity and morphology not relevant. KM Estimate was used.
Time frame: From first dose up to 43 months
EFS was defined as the time from the date of first dose until the date of documented relapse, treatment failure or death from any cause within 30 days after the last dose of study drug (whichever occurred first earliest of [relapse date, treatment failure date, death date] - first dose date + 1). Relapse was defined as a reappearance of leukemic blasts in the peripheral blood (> 2%) or ≥ 5% blasts in the bone marrow aspirate not attributable to any other cause or reappearance or new appearance of extramedullary leukemia or reappearance of significant numbers of peripheral blasts and an increase in the percentage of blasts in the bone marrow aspirate to > 25% not attributable to any other cause or reappearance or new appearance of extramedullary leukemia. KM Estimate was used.
Time frame: From first dose up to 43 months
OS was defined as the time from the date of first dose until the date of death from any cause (death date - first dose date + 1). For a Participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - first dose date + 1). KM Estimate was used.
Time frame: From first dose up to 43 months
Percentage of participants with CR was reported. CR: achieved morphologic leukemia-free state & their bone marrow was regenerating normal hematopoietic cells. If absolute neutrophil count (ANC) ≥ 1 × 10^9/L, platelet count (PC) ≥ 100 × 10^9/L, normal marrow differential < 5% blasts, & were red blood cell (RBC) and platelet transfusion independent (defined as 1 week without RBC transfusion & platelet transfusion prior to disease assessment). There was no evidence of extramedullary leukemia or Auer rods and blast counts in peripheral blood must be ≤ 2%.
Time frame: From first dose up to 43 months
Percentage of participants with best response (CRc + PR) was reported. CRc was defined as rate of all complete and incomplete remissions (CR + CR with incomplete platelet recovery [CRp] + CR with incomplete hematological recover [Cri]). CR, CRp and CRi were defined in Outcome measure # 3.
PR: achieved bone marrow regenerating normal hematopoietic cells with evidence of peripheral recovery with no (or only a few regenerating) circulating blasts with decrease of at least 50% in the percentage of blasts in bone marrow aspirate with total marrow blasts between 5% and 25%. Value ≤ 5% blasts was considered PR if Auer rods were present. No evidence of extramedullary leukemia.
Time frame: From first dose up to 43 months
Percentage of participants with CRh was reported. CRh: achieved marrow blasts < 5%, partial hematologic recovery ANC ≥ 0.5 × 10^9/L and platelets ≥ 50 × 10^9/L, no evidence of extramedullary leukemia and cannot be classified as CR. The blast counts in peripheral blood was ≤ 2%.
Time frame: From first dose up to 43 months
Percentage of participants with CR was reported. CR: bone marrow: ≤ 5% myeloblasts with normal maturation of all cell Lines, peripheral blood evaluation (hemoglobin (Hb) ≥ 11 g/dL, platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood).
Time frame: From first dose up to 43 months
Percentage of participants with HI was reported. HI: One measurement of the following for at least 8 weeks without cytotoxic therapy:
Time frame: From first dose up to 43 months
Percentage of participants with OR (CR + BM CR + PR + HI) was reported. CR, BM CR & PR achieved for minimum of 4 weeks.
CR: BM: ≤ 5% myeloblasts with normal maturation of all cell Lines peripheral blood evaluation (Hb) ≥ 11 g/dL platelets ≥ 100 × 10^9/L, neutrophils ≥ 1.0 × 10^9/L, 0% blasts in blood) BM CR: bone marrow ≤ 5% myeloblasts & decrease by ≥ 50% over pretreatment. PR: achieved all CR criteria except bone marrow blasts decreased ≥ 50% over pretreatment but still > 5% cellularity and morphology not relevant.
HI: One measurement of following for at least 8 weeks without cytotoxic therapy.
Astellas Pharma Global Development, Inc.
Industry
A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02492737
Acute Myeloid Leukemia (AML), Bone Marrow Diseases
Aurora, Colorado, United States
View Trial DetailsNCT00433745
Acute Myeloid Leukemia (AML), Bone Marrow Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT00071006
Acute Myeloid Leukemia (AML), Bone Marrow Diseases
Houston, Texas, United States
View Trial DetailsNCT07205523
Acute Myeloid Leukemia (AML), Anemia
Xining, Qinghai, China
View Trial Details